Ark Biosciences Completes Phase I Trial Of Antivirus Drug
05 Oct 2015
Ark Biosciences, a Shanghai biotech developing proprietary therapeutics for respiratory viral diseases and viral hepatitis, successfully completed a phase I clinical trial of its anti-respiratory syncytial virus (RSV) drug AK0529. The trial is a randomized, double-blind, placebo-controlled study of orally administered AK0529 that evaluates safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses. Ark had completed a Series A round led by Qiming and Morningside in April 2015 to help fund the advancement of AK0529.
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.